Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes
- PMID: 25288127
- DOI: 10.1007/s10545-014-9772-x
Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes
Abstract
Disorders of the glucose-6-phosphatase (G6Pase)/glucose-6-phosphate transporter (G6PT) complexes consist of three subtypes: glycogen storage disease type Ia (GSD-Ia), deficient in the liver/kidney/intestine-restricted G6Pase-α (or G6PC); GSD-Ib, deficient in a ubiquitously expressed G6PT (or SLC37A4); and G6Pase-β deficiency or severe congenital neutropenia syndrome type 4 (SCN4), deficient in the ubiquitously expressed G6Pase-β (or G6PC3). G6Pase-α and G6Pase-β are glucose-6-phosphate (G6P) hydrolases with active sites lying inside the endoplasmic reticulum (ER) lumen and as such are dependent upon the G6PT to translocate G6P from the cytoplasm into the lumen. The tissue expression profiles of the G6Pase enzymes dictate the disease's phenotype. A functional G6Pase-α/G6PT complex maintains interprandial glucose homeostasis, while a functional G6Pase-β/G6PT complex maintains neutrophil/macrophage energy homeostasis and functionality. G6Pase-β deficiency is not a glycogen storage disease but biochemically it is a GSD-I related syndrome (GSD-Irs). GSD-Ia and GSD-Ib patients manifest a common metabolic phenotype of impaired blood glucose homeostasis not shared by GSD-Irs. GSD-Ib and GSD-Irs patients manifest a common myeloid phenotype of neutropenia and neutrophil/macrophage dysfunction not shared by GSD-Ia. While a disruption of the activity of the G6Pase-α/G6PT complex readily explains why GSD-Ia and GSD-Ib patients exhibit impaired glucose homeostasis, the basis for neutropenia and myeloid dysfunction in GSD-Ib and GSD-Irs are only now starting to be understood. Animal models of all three disorders are now available and are being exploited to both delineate the disease more precisely and develop new treatment approaches, including gene therapy.
Similar articles
-
Molecular biology and gene therapy for glycogen storage disease type Ib.J Inherit Metab Dis. 2018 Nov;41(6):1007-1014. doi: 10.1007/s10545-018-0180-5. Epub 2018 Apr 16. J Inherit Metab Dis. 2018. PMID: 29663270 Review.
-
Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy.Nat Rev Endocrinol. 2010 Dec;6(12):676-88. doi: 10.1038/nrendo.2010.189. Epub 2010 Oct 26. Nat Rev Endocrinol. 2010. PMID: 20975743 Free PMC article. Review.
-
Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex.Curr Mol Med. 2002 Mar;2(2):121-43. doi: 10.2174/1566524024605798. Curr Mol Med. 2002. PMID: 11949931 Review.
-
Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy.Hepatology. 2012 Nov;56(5):1719-29. doi: 10.1002/hep.25717. Epub 2012 Aug 27. Hepatology. 2012. PMID: 22422504 Free PMC article.
-
The molecular basis of type 1 glycogen storage diseases.Curr Mol Med. 2001 Mar;1(1):25-44. doi: 10.2174/1566524013364112. Curr Mol Med. 2001. PMID: 11899241 Review.
Cited by
-
Development of minimally invasive 13C-glucose breath test to examine different exogenous carbohydrate sources in patients with glycogen storage disease type Ia.Mol Genet Metab Rep. 2022 May 11;31:100880. doi: 10.1016/j.ymgmr.2022.100880. eCollection 2022 Jun. Mol Genet Metab Rep. 2022. PMID: 35585965 Free PMC article.
-
Skimmin Improves Insulin Resistance via Regulating the Metabolism of Glucose: In Vitro and In Vivo Models.Front Pharmacol. 2020 Apr 29;11:540. doi: 10.3389/fphar.2020.00540. eCollection 2020. Front Pharmacol. 2020. PMID: 32425786 Free PMC article.
-
Recent development and gene therapy for glycogen storage disease type Ia.Liver Res. 2017 Sep;1(3):174-180. doi: 10.1016/j.livres.2017.12.001. Liver Res. 2017. PMID: 29576889 Free PMC article.
-
Classifying molecular phenotypes of G6PC variants for pathogenic properties and to guide therapeutic development.JIMD Rep. 2021 Mar 28;60(1):56-66. doi: 10.1002/jmd2.12215. eCollection 2021 Jul. JIMD Rep. 2021. PMID: 34258141 Free PMC article.
-
The SGLT2-inhibitor dapagliflozin improves neutropenia and neutrophil dysfunction in a mouse model of the inherited metabolic disorder GSDIb.Mol Genet Metab Rep. 2021 Oct 20;29:100813. doi: 10.1016/j.ymgmr.2021.100813. eCollection 2021 Dec. Mol Genet Metab Rep. 2021. PMID: 34712576 Free PMC article.
References
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical